Soleno Therapeutics (SLNO) Competitors $53.62 -3.10 (-5.47%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$53.06 -0.56 (-1.04%) As of 09/12/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. FEMY, IMVT, SOLV, PEN, STVN, GKOS, IRTC, BLCO, TMDX, and NVSTShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), and Envista (NVST). These companies are all part of the "medical" sector. Soleno Therapeutics vs. Its Competitors Femasys Immunovant Solventum Penumbra Stevanato Group Glaukos iRhythm Technologies Bausch + Lomb TransMedics Group Envista Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability. Is SLNO or FEMY more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -73.74% -56.67% Femasys -1,113.72%-713.74%-152.60% Which has higher earnings and valuation, SLNO or FEMY? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.14-12.95Femasys$1.63M7.84-$18.82M-$0.86-0.46 Do analysts recommend SLNO or FEMY? Soleno Therapeutics currently has a consensus target price of $115.09, indicating a potential upside of 114.64%. Femasys has a consensus target price of $7.33, indicating a potential upside of 1,770.27%. Given Femasys' higher probable upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to SLNO or FEMY? In the previous week, Soleno Therapeutics had 33 more articles in the media than Femasys. MarketBeat recorded 41 mentions for Soleno Therapeutics and 8 mentions for Femasys. Femasys' average media sentiment score of 0.74 beat Soleno Therapeutics' score of 0.55 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive Femasys 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, SLNO or FEMY? Soleno Therapeutics has a beta of -2.72, suggesting that its share price is 372% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.64, suggesting that its share price is 364% less volatile than the S&P 500. Do institutionals and insiders believe in SLNO or FEMY? 97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by insiders. Comparatively, 11.5% of Femasys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummarySoleno Therapeutics and Femasys tied by winning 8 of the 16 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.01B$2.59B$5.84B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-12.9523.8575.4125.98Price / SalesN/A527.96515.86180.60Price / CashN/A171.1637.5660.44Price / Book9.445.3712.156.29Net Income-$175.85M$32.95M$3.29B$271.07M7 Day Performance-23.15%1.28%0.74%3.87%1 Month Performance-30.69%5.61%5.00%5.49%1 Year Performance1.48%-1.67%62.55%25.86% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.4408 of 5 stars$53.62-5.5%$115.09+114.6%+1.5%$3.01BN/A-12.9530Trending NewsAnalyst UpgradeShort Interest ↑Analyst RevisionFEMYFemasys3.0889 of 5 stars$0.36-0.4%$7.33+1,965.1%-65.0%$11.57M$1.63M-0.4130News CoverageShort Interest ↑IMVTImmunovant2.4668 of 5 stars$14.69-0.9%$35.20+139.6%-45.5%$2.56BN/A-5.15120Positive NewsSOLVSolventum2.1096 of 5 stars$73.15+0.7%$85.75+17.2%+4.7%$12.67B$8.25B33.8622,000Analyst DowngradePENPenumbra4.5554 of 5 stars$272.96+0.5%$300.47+10.1%+46.3%$10.63B$1.19B72.604,500Positive NewsSTVNStevanato Group2.2061 of 5 stars€23.14-1.4%N/A+37.2%€7.01B€1.19B42.855,521News CoverageGap UpGKOSGlaukos4.7078 of 5 stars$95.86-0.7%$127.42+32.9%-34.5%$5.50B$383.48M-58.10780News CoveragePositive NewsAnalyst ForecastIRTCiRhythm Technologies1.3351 of 5 stars$169.98-0.9%$163.82-3.6%+134.7%$5.46B$591.84M-58.012,000News CoveragePositive NewsBLCOBausch + Lomb2.0998 of 5 stars$14.63+0.6%$15.56+6.3%-2.2%$5.18B$4.79B-18.7613,500News CoveragePositive NewsTMDXTransMedics Group2.5395 of 5 stars$114.96-1.5%$123.00+7.0%-24.3%$3.92B$441.54M59.57210NVSTEnvista3.9095 of 5 stars$21.15-0.5%$20.92-1.0%+8.5%$3.52B$2.51B66.0812,300Positive News Related Companies and Tools Related Companies Femasys Alternatives Immunovant Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives iRhythm Technologies Alternatives Bausch + Lomb Alternatives TransMedics Group Alternatives Envista Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone thought he was insane…SpaceX just struck a $17 billion deal with EchoStar for radio frequencies, and tech analyst Jeff Brown says it...Brownstone Research | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLNO Stock Alerts